×
ZIVO Bioscience EBITDA 2016-2024 | ZIVO
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
ZIVO Bioscience ebitda from 2016 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
View More
ZIVO Bioscience EBITDA 2016-2024 | ZIVO
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
ZIVO Bioscience ebitda from 2016 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$168.1B
Vertex Pharmaceuticals (VRTX)
$119.2B
Regeneron Pharmaceuticals (REGN)
$113.7B
Gilead Sciences (GILD)
$102.4B
Bristol Myers Squibb (BMY)
$101.3B
CSL (CSLLY)
$95.4B
GSK (GSK)
$84.1B
Alnylam Pharmaceuticals (ALNY)
$35B
Argenex SE (ARGX)
$32.8B
Biogen (BIIB)
$27.5B
BioNTech SE (BNTX)
$27.5B
Moderna (MRNA)
$24.5B
BeiGene (BGNE)
$20.1B
Illumina (ILMN)
$20.1B
Genmab (GMAB)
$15.8B
BioMarin Pharmaceutical (BMRN)
$13.1B
Vaxcyte (PCVX)
$12.7B
Exact Sciences (EXAS)
$12.5B
Insmed (INSM)
$12.5B
Incyte (INCY)
$12.2B
Bio-Techne Corp (TECH)
$11.9B
Sarepta Therapeutics (SRPT)
$11.9B
QIAGEN (QGEN)
$10.1B
Bio-Rad Laboratories (BIO.B)
$9.1B
Roivant Sciences (ROIV)
$8.7B
Ascendis Pharma (ASND)
$8.5B
Legend Biotech (LEGN)
$7.9B
Intra-Cellular Therapies (ITCI)
$7.9B
Repligen (RGEN)
$7.8B
Exelixis (EXEL)
$7.4B